Compensatory changes in the ubiquitin-proteasome system, brain-derived neurotrophic factor and mitochondrial complex II/III in YAC72 and R6/2 transgenic mice partially model Huntington's disease patients

Human Molecular Genetics

Volumn 17, Issue 20, 2008, Pages 3144-3153

  Seo, Hyemyung ^a,b   Kim, Woori ^b   Isacson, Ole ^a  

^a MCLEAN HOSPITAL   (United States)

^b Hanyang University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; BRAIN DERIVED NEUROTROPHIC FACTOR; CYTIDINE; GUANOSINE; PROTEASOME; SUCCINATE DEHYDROGENASE (UBIQUINONE); UBIQUINOL CYTOCHROME C REDUCTASE; UBIQUITIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE MODEL; ENZYME ACTIVITY; EXON; GENE MUTATION; HUNTINGTON CHOREA; MOUSE; MUTANT; NEUROPATHOLOGY; NONHUMAN; NUCLEOTIDE REPEAT; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; DISEASE MODELS, ANIMAL; ELECTRON TRANSPORT COMPLEX II; ELECTRON TRANSPORT COMPLEX III; HUMANS; HUNTINGTON DISEASE; MICE; MICE, TRANSGENIC; MODELS, NEUROLOGICAL; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; RECOMBINANT PROTEINS; UBIQUITIN;

MUS; MUS MUSCULUS;

EID: 53349101055     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddn211     Document Type: Article

References (54)

1. Ramaswamy, S., Shannon, K.M. and Kordower, J.H. (2007) Huntington's disease: Pathological mechanisms and therapeutic strategies. Cell Transplant, 16, 301-312.
2. de Pril, R., Fischer, D.F., Maat-Schieman, M.L., Hobo, B., de Vos, R.A., Brunt E.R., Hol, E.M., Roos, R.A. and van Leeuwen, F.W. (2004) Accumulation of aberrant ubiquitin induces aggregate formation and cell death in polyglutamine diseases. Hum. Mol. Genet, 13, 1803-1813.
3. Petrucelli, L. and Dawson, T.M. (2004) Mechanism of neurodegenerative disease: Role ofthe ubiquitin proteasome system. Ann. Med., 36 315-320.
4. Seo, H., Sonntag, K.C. and Isacson, O. (2004) Generalized brain and skin proteasome inhibition in Huntington's disease. Ann. Neurol., 56 319-328.
5. Seo, H., Sonntag, K.C., Kim, W., Cattaneo, E. and Isacson, O. (2007) Proteasome activator enhances survival of Huntington's disease neuronal model cells. PLoS ONE, 2, e238.
6. Canals, J.M., Checa, N., Marco, S., Akerud, P., Michels, A., Perez-Navarro, E., Tolosa, E., Arenas, E. and Alberch, J. (2001) Expression of brain-derived neurotrophic factor in cortical neurons is regulated by striatal target area. J. Neurosci., 21, 117-124.
7. Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B.R., Goffredo, D., Conti, L., MacDonald, M.E., Friedlander, R.M., Silani, V., Hayden, M.R. et al. (2001) Loss of huntington-mediated BDNF gene transcription in Huntington's disease. Science, 293, 493-498.
8. Zuccato, C., Liber, D., Ramos, C., Tarditi, A., Rigamonti, D., Tartari, M., Valenza, M. and Cattaneo, E. (2005) Progressive loss of BDNF in a mouse model of Huntington's disease and rescue by BDNF delivery. Pharmacol. Res., 52, 133-139.
9. Browne, S.E., Bowling, A.C., MacGarvey, U., Baik, M.J., Berger, S.C., Muqit, M.M., Bird, E.D. and Beal, M.F. (1997) Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia. Ann. Neurol., 41, 646-653.
10. Milakovic, T. and Johnson, G.V. (2005) Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin. J. Biol. Chem., 280, 30773-30782.
11. Benchoua, A., Trioulier, Y., Zala, D., Gaillard, M.C., Lefort, N., Dufour, N., Saudou, F., Elalouf, J.M., Hirsch, E., Hantraye, P., Deglon, N. and Brouillet, E. (2006) Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin. Mol. Biol. Cell, 17, 1652-1663.
12. Johnson, M.A., Rajan, V., Miller, C.E. and Wightman, R.M. (2006) Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease. J. Neurochem., 97, 737-746.
13. Gizatullina, Z.Z., Lindenberg, K.S., Harjes, P., Chen, Y., Kosinski, C.M., Landwehrmeyer, B.G., Ludolph, A.C., Striggow, F., Zierz, S. and Gellerich, F.N. (2006) Low stability of Huntington muscle mitochondria against Ca2 + in R6/2 mice. Ann. Neurol., 59, 407-411.
14. Hodgson, J.G., Agopyan, N., Gutekunst, C.A., Leavitt, B.R., LePiane, F., Singaraja, R., Smith, D.J., Bissada, N., McCutcheon, K., Nasir, J. et al. (1999) A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron, 23, 181-192.
15. Cepeda, C., Ariano, M.A., Calvert, C.R., Flores-Hernandez, J., Chandler, S.H., Leavitt, B.R., Hayden, M.R. and Levine, M.S. (2001) NMDA receptor function in mouse models of Huntington disease. J. Neurosci. Res., 66, 525-539.
16. Van Raamsdonk, J.M., Warby, S.C. and Hayden, M.R. (2007) Selective degeneration in YAC mouse models of Huntington disease. Brain Res. Bull., 72, 124-131.
17. Wheeler, V.C., White, J.K., Gutekunst, C.A., Vrbanac, V., Weaver, M., Li, X.J., Li, S.H., Yi, H., Vonsattel, J.P., Gusella, J.F. et al. (2000) Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Hum. Mol. Genet., 9, 503-513.
18. Diaz-Hernandez, M., Torres-Peraza, J., Salvatori-Abarca, A., Moran, M.A., Gomez-Ramos, P., Alberch, J. and Lucas, J.J. (2005) Full motor recovery despite striatal neuron loss and formation of irreversible amyloid-like inclusions in a conditional mouse model of Huntington's disease. J. Neurosci., 25, 9773-9781.
19. Diaz-Hernandez, M., Valera, A.G., Moran, M.A., Gomez-Ramos, P., Alvarez-Castelao, B., Castano, J.G., Hernandez, F. and Lucas, J.J. (2006) Inhibition of 26S proteasome activity by huntingtin filaments but not inclusion bodies isolated from mouse and human brain. J. Neurochem., 98, 1585-1596.
20. Tabrizi, S.J., Workman, J., Hart, P.E., Mangiarini, L., Mahal, A., Bates, G., Cooper, J.M. and Schapira, A.H. (2000) Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. Ann. Neurol., 47, 80-86.
21. Bates, G.P., Mangiarini, L., Mahal, A. and Davies, S.W. (1997) Transgenic models of Huntington's disease. Hum. Mol. Genet., 6 1633-1637.
22. Bowman, A.B., Yoo, S.Y., Dantuma, N.P. and Zoghbi, H.Y. (2005) Neuronal dysfunction in a polyglutamine disease model occurs in the absence of ubiquitin-proteasome system impairment and inversely correlates with the degree of nuclear inclusion formation. Hum. Mol. Genet., 14, 679-691.
23. Layfield, R. Lowe, J. and Bedford, L. (2005) The ubiquitin-proteasome system and neurodegenerative disorders. Essays Biochem., 41, 157-171.
24. Canals, J.M., Pineda, J.R., Torres-Peraza, J.F., Bosch, M., Martin-Ibanez, R., Munoz, M.T., Mengod, G., Ernfors, P. and Alberch, J. (2004) Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease. J. Neurosci., 24, 7727-7739.
25. Pineda, J.R., Canals, J.M., Bosch, M., Adell, A., Mengod, G., Artigas, F., Ernfors, P. and Alberch, J. (2005) Brain-derived neurotrophic factor modulates dopaminergic deficits in a transgenic mouse model of Huntington's disease. J. Neurochem., 93, 1057-1068.
26. Saydoff, J.A., Garcia, R.A., Browne, S.E., Liu, L., Sheng, J., Brenneman, D., Hu, Z., Cardin, S., Gonzalez, A., von Borstel, R.W. et al. (2006) Oral uridine pro-drug PN401 is neuroprotective in the R6/2 and N171-82Q mouse models of Huntington's disease. Neurobiol. Dis., 24, 455-465.
27. Spires, T.L., Grote, H.E., Varshney, N.K., Cordery, P.M., van Dellen, A., Blakemore, C. and Hannan, A.J. (2004) Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism. J. Neurosci., 24, 2270-2276.
28. del Toro, D., Canals, J.M., Gines, S., Kojima, M., Egea, G. and Alberch, J. (2006) Mutant huntingtin impairs the post-Golgi trafficking of brain-derived neurotrophic factor but not its Val66Met polymorphism. J. Neurosci., 26, 12748-12757.
29. Gines, S., Bosch, M., Marco, S., Gavalda, N., Diaz-Hernandez, M., Lucas, J.J., Canals, J.M. and Alberch, J. (2006) Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain. Eur. J. Neurosci., 23, 649-658.
30. Baquet, Z.C., Gorski, J.A. and Jones, K.R. (2004) Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cortical brain-derived neurotrophic factor. J. Neurosci, 24, 4250-4258.
31. Mufson, E.J. and Kordower, J.H. (1992) Cortical neurons express nerve growth factor receptors in advanced age and Alzheimer disease. Proc. Natl Acad. Sci. USA, 89, 569-573.
32. Mufson, E.J., Kroin, J.S., Sendera, T.J. and Sobreviela, T. (1999) Distribution and retrograde transport of trophic factors in the central nervous system: Functional implications for the treatment of neurodegenerative diseases. Prog. Neurobiol., 57, 451-484.
33. Isacson, O., Seo, H., Lin, L., Albeck, D. and Granholm, A.C. (2002) Alzheimer's disease and Down's syndrome: Roles of APP, trophic factors and ACh. Trends Neurosci., 25, 79-84.
34. Beal, M.F. (1994) Neurochemistry and toxin models in Huntington's disease. Curr. Opin. Neurol., 7, 542-547.
35. Brouillet, E., Jenkins, B.G., Hyman, B.T., Ferrante, R.J., Kowall, N.W., Srivastava, R., Roy, D.S., Rosen, B.R. and Beal, M.F. (1993) Age-dependent vulnerability of the striatum to the mitochondnal toxin 3-nitropropionic acid. J. Neurochem., 60, 356-359.
36. Saulle, E., Gubellini, P., Picconi, B., Centonze, D., Tropepi, D., Pisani, A., Morari, M., Marti, M., Rossi, L., Papa, M., Bernardi, G. and Calabresi, P. (2004) Neuronal vulnerability following inhibition of mitochondrial complex II: A possible ionic mechanism for Huntington's disease. Mol. Cell. Neurosci., 25, 9-20.
37. Brouillet, E., Jacquard, C., Bizat, N. and Blum, D. (2005) 3-Nitropropionic acid: A mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. J. Neurochem., 95, 1521-1540.
38. Bossi, S.R., Simpson, J.R. and Isacson, O. (1993) Age dependence of striatal neuronal death caused by mitochondnal dysfunction. Neuroreport, 4, 73-76.
39. Simpson, J.R. and Isacson, O. (1993) Mitochondrial impairment reduces the threshold for in vivo NMDA-mediated neuronal death in the striatum. Exp. Neurol., 121, 57-64.
40. Rossi, S., Prosperetti, C., Picconi, B., De Chiara, V., Mataluni, G., Bernardi, G., Calabresi, P. and Centonze, D. (2006) Deficits of glutamate transmission in the striatum of toxic and genetic models of Huntington's disease. Neurosci. Lett., 410, 6-10.
41. Oliveira, J.M., Chen, S., Almeida, S., Riley, R., Goncalves, J., Oliveira, C.R., Hayden, M.R., Nicholls, D.G., Ellerby, L.M. and Rego, A.C. (2006) Mitochondrial-dependent Ca2+ handling in Huntington's disease striatal cells: Effect of histone deacetylase inhibitors. J. Neurosci., 26, 11174-11186.
42. Oliveira, J.M., Jekabsons, M.B., Chen, S., Lin, A., Rego, A.C., Goncalves, J., Ellerby, L.M. and Nicholls, D.G. (2007) Mitochondrial dysfunction in Huntington's disease: The bioenergetics of isolated and in situ mitochondria from transgenic mice. J. Neurochem., 101 241-249.
43. Cui, L., Jeong, H., Borovecki, F., Parkhurst, C.N., Tanese, N. and Krainc, D. (2006) Transcriptional repression of PGC-1 alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell, 127, 59-69.
44. Jana, N.R., Zemskov, E.A., Wang, G. and Nukina, N. (2001) Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum. Mol. Genet. 10, 1049-1059.
45. Sommerfeld, M.T., Schweigreiter, R., Barde, Y.A. and Hoppe, E. (2000) Down-regulation of the neurotrophin receptor TrkB following ligand binding. Evidence for an involvement of the proteasome and differential regulation of TrkA and TrkB. J. Biol. Chem., 275, 8982-8990.
46. Perez-De La Cruz, V. and Santamaria, A. (2007) Integrative hypothesis for Huntington's disease: A brief review of experimental evidence. Physiol. Res., 56, 513-526.
47. Wang, C., Zhou, H., McGuire, J.R., Cerullo, V., Lee, B., Li, S. and Li, X. (2008) Suppression of neutrophil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin. J. Cell Biol., 181, 803-816.
48. Chou, S.Y., Weng, J.Y., Lai, H.L., Liao, F., Sun, S.H., Tu, P.H., Dickson, D.W. and Chern, Y. (2008) Expanded-polyglutamine huntingtin protein suppresses the secretion and production of a chemokine (CCL5/ RANTES) by astrocytes. J. Neurosci., 28, 3277-3290.
49. Tai, Y.F., Pavese, N., Gerhard, A., Tabrizi, S.J., Barker, R.A., Brooks, D.J. and Piccini, P. (2007) Microglial activation in presymtomatic Huntington's disease gene carriers. Brain, 130, 1759-1766.
50. Ryu, J.K., Choi, H.B. and McLarnon, J.G. (2006) Combined minocycline plus pyruvate treatment enhances effects of each agent to inhibit inflammation, oxidative damage, and neuronal loss in an excitotoxic animal model of Huntington's disease. Neuroscience, 141, 1835-1848.
51. Koprich, J.B., Reske-Nielsen, C., Mithal, P. and Isacson, O. (2008) Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease. J. Neuroinflamm., 5, 8.
52. Van Raamsdonk, J.M., Murphy, Z., Slow, E.J., Leavitt, B.R. and Hayden, M.R. (2005) Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease. Hum. Mol. Genet., 14, 3823-3835.
53. Van Raamsdonk, J.M., Pearson, J., Murphy, Z., Hayden, M.R. and Leavitt, B.R. (2006) Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease. BMC Neurosci., 7, 80.
54. Pedersen, P.L., Greenawalt, J.W., Reynafarje, B., Hullihen, J., Decker, G.L., Soper, J.W. and Bustamente, E. (1978) Preparation and characterization of mitochondria and submitochondrial particles of rat liver and liver-derived tissues. Methods Cell Biol., 20, 411-481.